JP2023533807A - 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 - Google Patents

自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 Download PDF

Info

Publication number
JP2023533807A
JP2023533807A JP2023502631A JP2023502631A JP2023533807A JP 2023533807 A JP2023533807 A JP 2023533807A JP 2023502631 A JP2023502631 A JP 2023502631A JP 2023502631 A JP2023502631 A JP 2023502631A JP 2023533807 A JP2023533807 A JP 2023533807A
Authority
JP
Japan
Prior art keywords
methyl
pyridin
dihydro
alkyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023502631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533807A5 (https=
JPWO2022013136A5 (https=
Inventor
デイ，ファビアン
ワン，シャオチン
チャン，ジーセン
ジュ，ウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2023533807A publication Critical patent/JP2023533807A/ja
Publication of JP2023533807A5 publication Critical patent/JP2023533807A5/ja
Publication of JPWO2022013136A5 publication Critical patent/JPWO2022013136A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023502631A 2020-07-14 2021-07-12 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 Ceased JP2023533807A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/101904 2020-07-14
CN2020101904 2020-07-14
CN2021094138 2021-05-17
CNPCT/CN2021/094138 2021-05-17
PCT/EP2021/069294 WO2022013136A1 (en) 2020-07-14 2021-07-12 Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Publications (3)

Publication Number Publication Date
JP2023533807A true JP2023533807A (ja) 2023-08-04
JP2023533807A5 JP2023533807A5 (https=) 2024-07-22
JPWO2022013136A5 JPWO2022013136A5 (https=) 2024-07-22

Family

ID=77126791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502631A Ceased JP2023533807A (ja) 2020-07-14 2021-07-12 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Country Status (6)

Country Link
US (1) US20240317735A1 (https=)
EP (1) EP4182032A1 (https=)
JP (1) JP2023533807A (https=)
CN (1) CN115835910A (https=)
TW (1) TW202216711A (https=)
WO (1) WO2022013136A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4196222A1 (en) * 2020-08-14 2023-06-21 Minerva Neurosciences, Inc. Condensed azacycles as sigma ligand compounds and uses thereof
PE20250401A1 (es) * 2021-09-24 2025-02-11 Hoffmann La Roche Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias
CN120230100B (zh) * 2025-05-30 2025-09-05 中国药科大学 一种咪唑并[1,2-a]吡嗪或咪唑并[1,2-a]吡啶类化合物及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2018218197A2 (en) * 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
WO2019126242A1 (en) * 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
JP2019531280A (ja) * 2016-09-09 2019-10-31 ノバルティス アーゲー エンドソームＴｏｌｌ様受容体の阻害剤としての化合物および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6306750B2 (ja) 2014-03-07 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン
JP7407740B2 (ja) 2018-05-18 2024-01-04 ノバルティス アーゲー Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
EP3802539B1 (en) 2018-06-05 2023-09-20 F. Hoffmann-La Roche AG Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MX2021012223A (es) * 2019-04-09 2021-11-03 Hoffmann La Roche Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
JP2019531280A (ja) * 2016-09-09 2019-10-31 ノバルティス アーゲー エンドソームＴｏｌｌ様受容体の阻害剤としての化合物および組成物
WO2018218197A2 (en) * 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
WO2019126242A1 (en) * 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors

Also Published As

Publication number Publication date
WO2022013136A1 (en) 2022-01-20
US20240317735A1 (en) 2024-09-26
EP4182032A1 (en) 2023-05-24
TW202216711A (zh) 2022-05-01
CN115835910A (zh) 2023-03-21

Similar Documents

Publication Publication Date Title
US12157746B2 (en) Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
WO2019238629A1 (en) Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
JP7692838B2 (ja) 自己免疫疾患の治療のためのヘキサヒドロ－１Ｈ－ピラジノ［１，２－ａ］ピラジン化合物
TW202024065A (zh) 用於治療自體免疫疾病之雜環基化合物
JP2023533807A (ja) 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物
JP2022501326A (ja) 自己免疫疾患の治療のための新規ピロリジンアミン化合物
JP7649306B2 (ja) 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物
TW202031650A (zh) 用於治療自體免疫疾病之吡唑化合物
JP7660114B2 (ja) 自己免疫疾患の処置用のヒドロピラジノ［１，２－ｄ］［１，４］ジアゼピン化合物
EP3623369B1 (en) Novel morpholinyl amine compounds for the treatment of autoimmune disease
JP7676391B2 (ja) 自己免疫疾患の処置のための１，８－ナフチリジン－２－オン化合物
US12503471B2 (en) Triazatricycle compounds for the treatment of autoimmune disease
US20240360126A1 (en) Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease
HK40086354A (zh) 用於治疗自身免疫性疾病的氢化异喹啉或氢化萘啶化合物
EA052162B1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
HK40048961A (en) 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus
HK40043698A (en) Pyrazolopyridine amine compounds for the treatment of autoimmune disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251014

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260224